Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10018416HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10019591HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10050130HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060226HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060735HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060227HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060228HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060225HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10062340HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TVIS10060224HBVENSG00000118271.12protein_codingTTRNoNo7276P02766
TCGA Plot Options
Drug Information
GeneTTR
DrugBank IDDB11644
Drug NameTafamidis
Target IDBE0000337
UniProt IDP02766
Regulation Typechaperone
PubMed IDs31735731
CitationsEndo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, Kuwahara K, Inomata T, Ueda M, Sekijima Y, Ando Y, Tsutsui H, Isobe M, Fukuda K: A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis. Circ J. 2019 Dec 25;84(1):15-17. doi: 10.1253/circj.CJ-19-0811. Epub 2019 Nov 16.
GroupsApproved; Investigational
Direct ClassificationPhenyl-1,3-oxazoles
SMILESOC(=O)C1=CC=C2N=C(OC2=C1)C1=CC(Cl)=CC(Cl)=C1
Pathways
PharmGKB
ChEMBLCHEMBL2103837